Aclarion (ACON) Projected to Post Quarterly Earnings on Wednesday

Aclarion (NASDAQ:ACON) is projected to issue its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Aclarion to post earnings of ($3.60) per share and revenue of $0.02 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 20, 2026 at 10:30 AM ET.

Aclarion Stock Down 0.8%

ACON traded down $0.02 on Friday, hitting $2.54. The company’s stock had a trading volume of 31,202 shares, compared to its average volume of 110,617. Aclarion has a 12 month low of $2.34 and a 12 month high of $229.50. The firm has a market cap of $2.16 million, a P/E ratio of -0.17 and a beta of 1.44. The company’s 50 day simple moving average is $4.20 and its 200-day simple moving average is $6.23.

Wall Street Analysts Forecast Growth

ACON has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aclarion in a report on Wednesday, January 21st. Wall Street Zen raised Aclarion from a “sell” rating to a “hold” rating in a report on Sunday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.